Skull Base Neoplasms

Assiut University

Skull Base Reconstruction After Endonasal Cranio-endoscopic Resection Using Autologus Grafts

bone window axial, coronal and sagittal cuts to measure preoperative skull base defect size

Coronal, axial and sagittal MRI in T1 and T2 signals measures postoperative tumor, to assess the repaired defect after the surgery

Coronal, axial and sagittal MRI in T1 and T2 signals to assess the repaired defect after the surgery

Coronal, axial and sagittal MRI in T1 and T2 signals to assess the repaired defect after the surgery, recurrence of tumor

identification of possible complication that will occur during resection of skull base and removal of tumors

history of CSF leakage confirmed by endoscopic examination

second surgical intervention to explore the grafted defect

using 4 mm 0-degree endoscope to measure graft condition and visualize any CSF fistula

Coronal, axial and sagittal MRI in T1 and T2 signals measures preoperative tumor size

identification of the type of the pathology

Ahmed Gamal Sholkamy

Congenital Hyperinsulinism

Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg

Sandostatine LP

Necker Hospital

Sandostatine® LP and Hyperinsulinism

Replace Sandostatine® in Three Daily Subcutaneous Injections by a Single Intramuscular Injection of Sandostatine® LP Per Month in Patients With a Diffuse Form of Hyperinsulinism

Assistance Publique - Hôpitaux de Paris

Novartis

Acromegaly

ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.

Lanreotide-Autogel 120 mg

Annamaria Colao

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

A Multicenter, Open, Prospective, Observational Study to Investigate the Effect of Lanreotide Autogel 120 mg on Control of GH and IGF-I Excess and Tumor Shrinkage in Newly Diagnosed Patients With Acromegaly

acromegaly/kaalium

Skull Base Reconstruction After Endonasal Cranio-endoscopic Resection Using Autologus Grafts

Sandostatine® LP and Hyperinsulinism

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus